Adaptive Biotechnologies exec logs stock sales, option use
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of pre-planned stock transactions in common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of pre-planned stock transactions in common stock. Under a Rule 10b5-1 trading plan, she exercised stock options to acquire a total of 56,047 shares at exercise prices of $8.46 and $12.14 per share, then sold 69,061 shares in open‑market transactions at weighted average prices in the mid‑$14 range. Following these exercises and sales, she continues to hold a substantial direct ownership position in Adaptive Biotechnologies common stock.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
11 txns
Insider
RUBINSTEIN JULIE
Role
President and COO
Sold
69,061 shs ($1.01M)
Approx. gross sale proceeds
$1.01M
Approx. exercise cost
$518K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 11,881 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $8.46 | $125K |
| Exercise | Common Stock | 11,881 | $12.14 | $144K |
| Sale | Common Stock | 30,941 | $14.66 | $454K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $8.46 | $125K |
| Sale | Common Stock | 19,060 | $14.55 | $277K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $8.46 | $125K |
| Sale | Common Stock | 19,060 | $14.57 | $278K |
Holdings After Transaction:
Stock Option (right to buy) — 484,381 contracts (Direct);
Common Stock — 395,146 shares (Direct)
Footnotes (6)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.38 to $14.91, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.14 to $14.82, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.18 to $15.13, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F5. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F6. The option is fully vested and exercisable.
Key Figures
Shares sold: 69,061 shares
Options exercised: 56,047 shares
Sale price example: $14.66 per share
+5 more
8 metrics
Shares sold
69,061 shares
Total common stock sold across reported transactions
Options exercised
56,047 shares
Total shares acquired through option exercises (M code)
Sale price example
$14.66 per share
Weighted average price for one 2026-04-21 sale
Sale price example
$14.55 per share
Reported price for a 2026-04-20 sale
Option strike price
$8.46 per share
Exercise price for one stock option grant
Option strike price
$12.14 per share
Exercise price for another stock option grant
Post-sale holdings example
395,146 shares
Direct common stock held after a 2026-04-21 sale
Option expiration dates
2032-03-04 and 2033-03-06
Expiration dates for remaining stock option grants
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (right to buy), fully vested and exercisable, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported for this transaction is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
fully vested and exercisable financial
"The option is fully vested and exercisable."
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did ADPT executive Julie Rubinstein report?
Julie Rubinstein reported option exercises and open-market sales of Adaptive Biotechnologies common stock. She exercised options for 56,047 shares and sold 69,061 shares in multiple trades, all executed under a pre-established Rule 10b5-1 trading plan.
What stock options did Julie Rubinstein exercise at Adaptive Biotechnologies (ADPT)?
She exercised stock options covering 56,047 shares of Adaptive Biotechnologies common stock. These options had exercise prices of $8.46 and $12.14 per share, and were fully vested or vesting according to the schedules described in the filing’s footnotes.
Were Julie Rubinstein’s ADPT stock sales pre-planned under Rule 10b5-1?
Yes. The filing states the transactions were executed under a Rule 10b5-1 trading plan adopted on November 18, 2025. Such plans allow insiders to schedule trades in advance, providing structure around timing and reducing discretion when trades actually occur.
What remains of Julie Rubinstein’s stock options at Adaptive Biotechnologies (ADPT)?
After these exercises, certain options remain outstanding with expiration dates extending to 2032-03-04 and 2033-03-06. The filing notes that at least one option grant is fully vested and exercisable, reflecting ongoing equity-based compensation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
